Medistim ASA MEDI
OSL · Norway · Health Technology
NOK 253.000.00 (0.00%)
Market closed· · NOK · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · NOK · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Medistim ASA (FRA:MD1) posts record Q2 2026 results with 27.5% currency-neutral growth, raises long-term revenue target to NOK1 billion.
In recent weeks, the pan-European STOXX Europe 600 Index has experienced modest gains amid easing geopolitical tensions and robust corporate earnings, though market sentiment remains cautious due to potential U.S. tariff threats on EU goods. Against this backdrop of fluctuating market conditions, identifying promising small-cap stocks requires a keen eye for companies with strong fundamentals and growth potential that can navigate economic uncertainties effectively.
Medistim ASA (STU:MD1) reports robust growth with record sales and strategic initiatives, despite facing regional sales variability and tariff impacts.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.